Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within weeks prior to registration. Prior participation in an investigational study (drug, procedure or device) within days of study day . Participation in an interventional, investigational study within weeks of the first dose of study treatment. Prior participation in a clinical study of viagenpumatucel-L Participation in other studies involving investigational drug(s) within weeks prior to study entry and/or during study participation. Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation Prior participation in an investigational study within days of study day Participation in any investigational drug study within weeks preceding enrollment Participation in other studies involving investigational drug(s) within weeks prior to study entry and/or during study participation Current enrollment in an investigational drug or device study or participation in such a study within days of cycle day . Prior participation in this study Participation in another investigational drug study in the prior weeks Participation in a prior investigational study within weeks prior to enrollment or longer if required by local regulation Participation in an investigational drug or device study or treatment with any antineoplastic agent within days of the first day of dosing on this study Participation in an investigational drug or device study within days of the first day of dosing on this study Participation in an investigational new drug trial within days prior to initiating treatment on study Subjects with leukemia are not eligible for study participation Participation in an investigational drug study or history of receiving any investigational treatment within days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer. Discontinued study participation in Verastem-sponsored IPI-- study Participation in other studies involving investigational drug(s) within days prior to study entry and/or during study participation; Part : able to understand the recommendations for participation in the study Participation in any investigational drug study within weeks preceding the start of study treatment Participation in a prior investigational study within days prior to enrollment Current or recent treatment with another investigational drug within days of first study treatment dosing or earlier participation in this study Current or recent (within days of first study dosing) treatment with another investigational drug or participation in another investigational study Concurrent participation in any other investigational study Participation in any investigational drug study within weeks preceding the start of study treatment; patients are not permitted to participate in another investigational drug study while being treated on this protocol Participation in another research study involving an investigational agent within days prior to consent or projected study participation during the days post study randomization. Participation in a therapeutic research study or receipt of an investigational drug within weeks of leukapheresis Participation in an interventional, investigational study within weeks of the first dose of study treatment. Participation in another investigational drug study in the prior weeks Participation in an investigational anti-cancer study within weeks prior to day - (beginning of loading phase) Participation in any investigational drug study within weeks preceding the start of study treatment Current enrollment in an investigational drug or device study or participation in such a study within weeks of cycle , day Participation in any other investigational drug study within weeks of study enrollment Participation in other studies involving investigational drug(s) within weeks prior to study participation and/or during study participation. Current enrollment in an investigational drug or device study or participation in such a study within days of enrollment Previous participation in a stem cell study within last days Participation in an investigational therapeutic study within weeks prior to first dose Participation in any investigational drug study within weeks preceding the start of study treatment Participation in any investigational drug study within weeks preceding the start of study treatment Participation in any investigational drug study within weeks preceding the start of study treatment Current participation in other clinical study Participation in any clinical study or having taken any investigational therapy within days. current participation in other clinical study Participation in other studies involving investigational drug(s) (Phases -) within weeks of registering for the current study and/or during study participation. Participation in other studies involving investigational drug(s) (Phases -) before the current study begins and/or during study participation. Simultaneous participation in any other study involving investigational drugs or having participated in a study less than weeks prior to treatment in this study Female patients may not be breastfeeding at screening and must not breastfeed during study participation through days after the last dose of study drug. Participation in other study using an investigational or experimental therapy or procedure within weeks or half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study Participation in any investigational drug study within weeks preceding the start of study treatment Prior participation in an investigational study (procedure or device) within days of study day Previous participation in a clinical study of Kevetrin Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN-) Participation in another clinical study with an investigational drug within days of Screening. Participated in any previous study of aprepitant or fosaprepitant, or taken an investigational drug within weeks prior to study participation Current participation in a treatment study or past participation in a study of an investigational agent within weeks before the first dose of study treatment Current participation in a treatment study or past participation in a study of an investigational agent within weeks before the first dose of study treatment Females must agree to abstain from breastfeeding during study participation and days after study drug discontinuation Participation in an investigational therapeutic study within days of initiation of study drug treatment Likely to continue to need treatment of OIC for the duration of participation in the study. Participation in a study with an investigational drug from weeks prior to study start until study end Participation in any other clinical study within the last weeks prior to the start of the study Female patients must not be breastfeeding at screening nor during the study participation until days after the last dose of the study drug. Female patients must not be breastfeeding at screening nor during the study participation until days after the last dose of study drug. Concomitant participation in any other investigational treatment study; simultaneous participation in non-therapeutic or observational studies will not be an exclusion criterion Declined participation in the study Approval of Oncology provider for participation in this study Participation in any investigational drug study within weeks preceding the start of study treatment Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN-) Participation in an interventional, investigational non-immunotherapy study within weeks of the first dose of study treatment. Participation in any other investigational treatment within the weeks prior to enrollment or concurrent with this study. Participation in another clinical study within days of the day chemotherapy is initiated, in which the study drug or device may influence hematopoiesis. Co-enrollment in another study is allowed in cases where the investigational therapy under study is a version of an acceptable chemotherapy regimen for this study per the inclusion criteria. Previous participation in this study Participation in any study with an investigational compound or device within days prior to signing informed consent Participation in other study using an investigational or experimental therapy or procedure within weeks or half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study Participation in other research protocols does not exclude a patient from participation in this study Participation in any other study in last days Participation in another clinical study in the month preceding this study Participation in other clinical study within the last days Participation in a therapeutic clinical study within weeks before study drug treatment (for small-molecule targeted agents, this non-participation period is weeks or half-lives, whichever is longer), or current participation in other investigational procedures. Participation in more than research studies in the past months. Participation in a smoking study in the past months. Participation in a study which involved medication within the last month